SCHEMBL3090932

SCHEMBL3090932

CCCC(CC)CCCC[O]

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 0.42
ALDH1A1 P00352 4/20 0.41
TDP1 Q9NUW8 2/20 0.41
CYP3A4 P08684 5/20 0.39
TSHR P16473 4/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.36
ATM Q13315 1/20 0.34
OPRM1 P35372 1/20 0.33
PRSS1 P07477 1/20 0.32
PRSS2 P07478 1/20 0.32
PRSS3 P35030 1/20 0.32
TP53 P04637 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA7 P43166 1/20 0.31
CA14 Q9ULX7 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3100767 0.98 CA2 (0.41) CA2ALDH1A1TDP1CYP3A4TSHR
SCHEMBL979077 0.92 CA2 (0.43) CA2ALDH1A1TDP1CYP3A4TSHR
SCHEMBL11607418 0.88 LMNA (0.50) CA2ALDH1A1TDP1CYP3A4TSHR
SCHEMBL3101340 0.88 LMNA (0.50) CA2ALDH1A1TDP1CYP3A4TSHR
SCHEMBL3084643 0.88 LMNA (0.50) CA2ALDH1A1TDP1CYP3A4TSHR
SCHEMBL23498284 0.88 ALDH1A1 (0.50) CA2ALDH1A1TDP1CYP3A4TSHR
SCHEMBL3104066 0.88 ALDH1A1 (0.50) CA2ALDH1A1TDP1CYP3A4TSHR
SCHEMBL3100324 0.88 ALDH1A1 (0.50) CA2ALDH1A1TDP1CYP3A4TSHR
SCHEMBL1441655 0.87 ALDH1A1 (0.40) CA2ALDH1A1TDP1CYP3A4TSHR
SCHEMBL3097258 0.85 CA2 (0.47) CA2ALDH1A1TDP1CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023223888-A1 METHOD FOR PRODUCING POLYCARBONATE RESIN, AND ALICYCLIC POLYCARBONATE RESIN 旭化成株式会社 2023-11-23 WO disclosed
CN-109721723-B Surfactant, method for producing the same, and solution containing the same 中日合成化学股份有限公司 2021-07-06 CN disclosed
CN-109721723-A Interfacial agent, its manufacturing method and the solution comprising this interfacial agent 中日合成化学股份有限公司 2019-05-07 CN disclosed
US-20100279963-A1 DICARBONYL DERIVATIVES AND METHODS OF USE ABRAXIS BIOSCIENCE, LLC (US) 2010-11-04 US disclosed
US-7799954-B2 Dicarbonyl derivatives and methods of use ABRAXIS BIOSCIENCE, LLC (US) 2010-09-21 US disclosed
US-7674816-B2 Substituted melatonin derivatives, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, LLC (US) 2010-03-09 US disclosed
EP-2125694-A2 DICARBONYL DERIVATIVES AND METHODS OF USE Abraxis BioScience, Inc. (US) 2009-12-02 EP disclosed
EP-1701718-A4 SUBSTITUTED MELATONIN DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE LLC (US) 2009-06-24 EP disclosed
EP-1976505-A1 COMBRETASTATIN DERIVATIVES AND RELATED THERAPEUTIC METHODS Abraxis BioScience, Inc. (US) 2008-10-08 EP disclosed
US-20080146586-A1 DICARBONYL DERIVATIVES AND METHODS OF USE ABRAXIS BIOSCIENCE (US) 2008-06-19 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5248538-A SULFONAMIDO OR AMIDO SUBSTITUTED PHTHALOCYANINES FOR OPTICAL RECORDING EASTMAN KODAK COMPANY (US) 1993-09-28 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0519395-A1 Sulfonamido or amido substituted phthalocyanines for optical recording EASTMAN KODAK COMPANY (US) 1992-12-23 EP disclosed
CN-1059720-A Radicicol derivatives, its preparation method and anti-tumor activity thereof SANKYO CO (JP) 1992-03-25 CN disclosed
WO-1991018905-A1 RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY SANKYO COMPANY LIMITED (JP) 1991-12-12 WO disclosed
EP-0460950-A1 Radicicol derivatives, their preparation and their anti-tumour activity Sankyo Company Limited (JP) 1991-12-11 EP disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146586-A1 DICARBONYL DERIVATIVES AND METHODS OF USE AADAC, DCK, MLYCD CA2 1127/4885ALDH1A1 1688/4885TDP1 2676/4885
US-20100279963-A1 DICARBONYL DERIVATIVES AND METHODS OF USE AADAC, DCK, MLYCD CA2 1127/4885ALDH1A1 1688/4885TDP1 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.